DOCSLIB.ORG

Neuronal Degeneration and Mitochondrial Dysfunction

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Neuronal Degeneration and Mitochondrial Dysfunction Neuronal degeneration and mitochondrial dysfunction Eric A. Schon, Giovanni Manfredi J Clin Invest. 2003;111(3):303-312. https://doi.org/10.1172/JCI17741. Perspective Over the last decade, the underlying genetic bases of several neurodegenerative disorders, including Huntington disease (HD), Friedreich ataxia, hereditary spastic paraplegia, and rare familial forms of Parkinson disease (PD), Alzheimer disease (AD), and amyotrophic lateral sclerosis (ALS), have been identified. However, the etiologies of sporadic AD, PD, and ALS, which are among the most common neurodegenerative diseases, are still unclear, as are the pathogenic mechanisms giving rise to the various, and often highly stereotypical, clinical features of these diseases. Despite the differential clinical features of the various neurodegenerative disorders, the fact that neurons are highly dependent on oxidative energy metabolism has suggested a unified pathogenetic mechanism of neurodegeneration, based on an underlying dysfunction in mitochondrial energy metabolism. Mitochondria are the seat of a number of important cellular functions, including essential pathways of intermediate metabolism, amino acid biosynthesis, fatty acid oxidation, steroid metabolism, and apoptosis. Of key importance to our discussion here is the role of mitochondria in oxidative energy metabolism. Oxidative phosphorylation (OXPHOS) generates most of the cell’s ATP, and any impairment of the organelle’s ability to produce energy can have catastrophic consequences, not only due to the primary loss of ATP, but also due to indirect impairment of “downstream” functions, such as the maintenance of organellar and cellular calcium homeostasis. Moreover, deficient mitochondrial metabolism may generate reactive oxygen species […] Find the latest version: https://jci.me/17741/pdf PERSPECTIVE Neurodegeneration | Serge Przedborski, Series Editor Neuronal degeneration and mitochondrial dysfunction Eric A. Schon1,2 and Giovanni Manfredi3 1Department of Neurology, and 2Department of Genetics and Development, Columbia University, New York, New York, USA 3Department of Neurology and Neuroscience, Weill Medical College of Cornell University, New York, New York, USA J. Clin. Invest. 111:303–312 (2003). doi:10.1172/JCI200317741. Over the last decade, the underlying genetic bases of produce energy can have catastrophic consequences, not several neurodegenerative disorders, including Hunt- only due to the primary loss of ATP, but also due to indi- ington disease (HD), Friedreich ataxia, hereditary spas- rect impairment of “downstream” functions, such as the tic paraplegia, and rare familial forms of Parkinson dis- maintenance of organellar and cellular calcium home- ease (PD), Alzheimer disease (AD), and amyotrophic ostasis. Moreover, deficient mitochondrial metabolism lateral sclerosis (ALS), have been identified. However, may generate reactive oxygen species (ROS) that can the etiologies of sporadic AD, PD, and ALS, which are wreak havoc in the cell. It is for these reasons that mito- among the most common neurodegenerative diseases, chondrial dysfunction is such an attractive candidate for are still unclear, as are the pathogenic mechanisms giv- an “executioner’s” role in neuronal degeneration. ing rise to the various, and often highly stereotypical, The mitochondrion is the only organelle in the cell, clinical features of these diseases. Despite the differen- aside from the nucleus, that contains its own genome tial clinical features of the various neurodegenerative and genetic machinery. The human mitochondrial disorders, the fact that neurons are highly dependent genome (1) is a tiny 16.6-kb circle of double-stranded on oxidative energy metabolism has suggested a uni- mitochondrial DNA (mtDNA) (Figure 1). It encodes 13 fied pathogenetic mechanism of neurodegeneration, polypeptides, all of which are components of the respi- based on an underlying dysfunction in mitochondrial ratory chain/OXPHOS system, plus 24 genes, specify- energy metabolism. ing two ribosomal RNAs (rRNAs) and 22 transfer RNAs Mitochondria are the seat of a number of important (tRNAs), that are required to synthesize the 13 polypep- cellular functions, including essential pathways of inter- tides. Obviously, an organelle as complex as a mito- mediate metabolism, amino acid biosynthesis, fatty acid chondrion requires more than 37 gene products; in fact, oxidation, steroid metabolism, and apoptosis. Of key about 850 polypeptides, all encoded by nuclear DNA importance to our discussion here is the role of mito- (nDNA), are required to build and maintain a func- chondria in oxidative energy metabolism. Oxidative tioning organelle. These proteins are synthesized in the phosphorylation (OXPHOS) generates most of the cell’s cytoplasm and are imported into the organelle, where ATP, and any impairment of the organelle’s ability to they are partitioned into the mitochondrion’s four main compartments — the outer mitochondrial mem- brane (OMM), the inner mitochondrial membrane Address correspondence to: Eric A. Schon, Department of (IMM), the intermembrane space (IMS), and the matrix, Neurology, P&S 4-431, Columbia University, 630 West 168th located in the interior (the organelle’s “cytoplasm”). Of Street, New York, New York 10032, USA. Phone: (212) 305-1665; the 850 proteins, approximately 75 are structural com- Fax: (212) 305-3986; E-mail: [email protected]. Conflict of interest: The authors have declared that no conflict of ponents of the respiratory complexes (Figure 2) and at interest exists. least another 20 are required to assemble and maintain Nonstandard abbreviations used: Huntington disease (HD); them in working order. The five complexes of the respi- Parkinson disease (PD); familial Parkinson disease (FPD); ratory chain/OXPHOS system — complexes I (NADH Alzheimer disease (AD); familial Alzheimer disease (FAD); ubiquinone oxidoreductase), II (succinate ubiquinone amyotrophic lateral sclerosis (ALS); sporadic amyotrophic lateral sclerosis (SALS); oxidative phosphorylation (OXPHOS); reactive oxidoreductase), III (ubiquinone–cytochrome c reduc- oxygen species (ROS); mitochondrial DNA (mtDNA); ribosomal tase), IV (cytochrome c oxidase), and V (ATP synthase) RNA (rRNA); transfer RNA (tRNA); nuclear DNA (nDNA); inner — are all located in the IMM. There are also two electron mitochondrial membrane (IMM); intermembrane space (IMS); carriers, ubiquinone (also called coenzyme Q), located mitochondrial encephalomyopathy with lactic acidosis and in the IMM, and cytochrome c, located in the IMS. strokelike episodes (MELAS); myoclonus epilepsy with ragged-red fibers (MERRF); ragged-red fiber (RRF); Kearns-Sayre syndrome Besides the fact that it operates under dual genetic (KSS); progressive external ophthalmoplegia (PEO); cytochrome c control, four other features unique to the behavior of oxidase (CCO); Leber hereditary optic neuropathy (LHON); this organelle are important in understanding mito- Leigh syndrome (LS); Friedreich ataxia (FRDA); mitochondrial chondrial function in neurodegeneration. First, as superoxide dismutase (Mn-SOD); Cu,Zn-superoxide dismutase (Cu,Zn-SOD); β-amyloid peptide (Aβ); progressive supranuclear opposed to the nucleus, in which there are two sets of palsy (PSP); terminal deoxynucleotidyl transferase–mediated chromosomes, there are thousands of mtDNAs in each dUTP nick end-labeling (TUNEL). cell, with approximately five mtDNAs per organelle. The Journal of Clinical Investigation | February 2003 | Volume 111 | Number 3 303 ited mutations in mtDNA are recessive, that is, a very high amount of mutated mtDNA must be present (typ- ically more than 70% of the total population of mtDNAs) in order to cause overt dysfunction. Since mtDNA encodes subunits of the respiratory complex- es, pathogenic mutations in mtDNA cause diseases arising from problems in OXPHOS. On the other hand, mutations in nucleus-encoded proteins that are targeted to mitochondria, or that affect organellar function indirectly, can affect almost any aspect of cel- lular function, not just oxidative energy metabolism. Neurodegenerative diseases associated with mutations in mitochondrial genes Diseases associated with mtDNA mutations are typi- cally heterogeneous and are often multisystemic. Since heart, skeletal muscle, and brain are among the most energy-dependent tissues of the body, it is not surpris- Figure 1 ing that many mitochondrial disorders are encephalo- Map of the human mitochondrial genome (1). Polypeptide-coding genes cardiomyopathies. For example, mutations in the (boldface) are outside the circle and specify seven subunits of NADH Leu(UUR) dehydrogenase–coenzyme Q oxidoreductase (ND), one subunit of coen- tRNA gene cause mitochondrial encephalomy- zyme Q–cytochrome c oxidoreductase (Cyt b), three subunits of opathy with lactic acidosis and strokelike episodes cytochrome c oxidase (CCO), and two subunits of ATP synthase (A) (see (MELAS), mutations in tRNALys cause myoclonus also Figure 2). Protein synthesis genes (12S and 16S rRNAs, and 22 epilepsy with ragged-red fibers (MERRF), and large- tRNAs [one-letter code]) are inside the circle. Mutations in mtDNA asso- scale spontaneous deletions cause Kearns-Sayre syn- ciated with MELAS and MERRF, and mutations with features of neuro- drome (KSS) and progressive external ophthalmoplegia degenerative disorders, such as ataxia, chorea, dystonia, motor neuron (PEO) (2). While these diseases are clinically distinct, disease (MND), and parkinsonism, are boxed. A complete list of patho- they share a number
Load more

Recommended publications
  • Diseases/Symptoms Reported to Be Associated with Lyme Disease
    Diseases/Symptoms Reported to be Associated with Lyme Disease Abdominal pseudo-eventration Abdominal wall weakness Acrodermatitis chronica atrophicans (ACA) Acute Acral Ischemia Acute conduction disorders Acute coronary syndrome Acute exogenous psychosis Acute febrile illness Acute hemiparesis Acute ischaemic pontine stroke Acute meningitis Acute myelo-meningo-radiculitis Acute myelitis Acute pediatric monoarticular arthritis Acute peripheral facial palsy Acute perimyocarditis Acute posterior multifocal placoid pigment epitheliopathy (APMPPE) Acute pyogenic arthritis Acute reversible diffuse conduction system disease Acute septic arthritis Acute severe encephalitis Acute transitory auriculoventricular block Acute transverse myelitis Acute urinary retention Acquired Immune Deficiency Syndrome (AIDS) Algodystrophy Allergic conditions Allergic conjunctivitis Alopecia Alzheimer’s Disease Amyotrophic lateral sclerosis (ALS - Lou Gehrig's Disease) Amyotrophy Anamnesis Anetoderma Anorexia nervosa Anterior optic neuropathy Antepartum fever Anxiety Arrhythmia Arthralgia Arthritis Asymmetrical hearing loss Ataxic sensory neuropathy Atraumatic spontaneous hemarthrosis Atrioventricular block Attention Deficit Disorder (ADD) Attention Deficit Hyperactivity Disorder (ADHD) Back pain without radiculitis Bannwarth’s Syndrome Behcet's disease Bell’s Palsy Benign cutaneous lymphocytoma Benign lymphocytic infiltration (Jessner-Kanof) Bilateral acute confluent disseminated choroiditis Bilateral carpal tunnel syndrome Bilateral facial nerve palsy Bilateral
    [Show full text]
  • 55400-Neuropathdementiav5
    08/11/2019 Bodian silver method Neuropathology of the Dementia Spectrum Charles Duyckaerts Escourolle Neuropathology Lab Alzheimer-Prion team ICM Pitié-Salpêtrière Senile plaquePitié-Salpêtrière Neurofibrillary tangle 12 Aβ accumulation + tauopathy = Alzheimer disease (please note: no neuronal loss in criteria) Pitié-Salpêtrière Pitié-Salpêtrière 34 1 08/11/2019 BRAAK STAGES : tau pathology THAL PHASES : Aβ pathology I II 1 23 III IV 4 5 V VI Braak and Braak. Acta Neuropathol 1991 Thal et al. Neurology 2002 Pitié-Salpêtrière Pitié-Salpêtrière 56 Pick’s circumscribed atrophy Pitié-Salpêtrière α-synuclein IHC Pitié-Salpêtrière 78 2 08/11/2019 Dementia (~1920) Alzheimer disease Pick disease (Pick circumscribed atrophy) Alzheimer A (1911) Uber eigenartige Krankheitsfälle des späteren Alters. Zentralblatt Gesam Neurol Psychiat 4: 356- Pitié-Salpêtrière Pitié-Salpêtrière 385 910 Pick disease Pick disease (Pick body disease) is also a tauopathy Tau IHC Pitié-Salpêtrière Pitié-Salpêtrière 11 12 3 08/11/2019 Fronto-temporal dementia with 1- behavioral changes 2- semantic dementia 3- progressive non-fluent aphasia Pick disease (with Pick bodies) « Pick without Pick body » R. Escourolle. 1957 & S. Brion Type C of Tissot, Constantinidis & Richard, 1975 Previously « Atypical Pick disease » Knopman DS, Mastri AR, Frei WH, Sung JH, Rustan T (1990) Dementia lacking distinctive histologic feature: a common non-Alzheimer degenerative dementia. Neurology 40: 251-256 Pitié-Salpêtrière Pitié-Salpêtrière 13 14 Mutations in the tau gene in frontotemporal dementia
    [Show full text]
  • Case Report Reversible Cortical Blindness and Convulsions with Cyclosporin a Toxicity in a Patient Undergoing Allogeneic Peripheral Stem Cell Transplantation
    Bone Marrow Transplantation, (1997) 20, 793–795 1997 Stockton Press All rights reserved 0268–3369/97 $12.00 Case report Reversible cortical blindness and convulsions with cyclosporin A toxicity in a patient undergoing allogeneic peripheral stem cell transplantation B Madan and SA Schey Department of Haematology, Guy’s Hospital, London, UK Summary: one course each of MACE (mitozantrone on days 1, 3 and 5, cytosine arabinoside on days 1–10, etoposide on days 1– A 40-year-old woman underwent allogeneic peripheral 5) and ICE (idarubicin on days 1 and 2, cytosine arabino- blood stem cell transplantation for relapsed AML-M6. side on days 1–3, etoposide on days 1–3). She achieved She developed graft-versus-host disease on day +15 complete remission after her first induction but relapsed post-transplant, for which she was treated with cyclo- within 1 month of completion of ICE chemotherapy. In sporin A and methyl prednisolone. On day +19 she March 1996 she was given mitoxantrone, cytosine arabino- developed cortical blindness, headache and convulsions side and PSC-833 (a cyclosporin D analogue) as per relapse which were associated with white matter changes on protocol and achieved complete remission. In July 1996, MRI scanning of the head and elevated cyclosporin A she received an allogeneic peripheral stem cell transplant levels. A diagnosis of cyclosporin A encephalopathy was from her HLA-identical sister following conditioning with made and cyclosporin A was discontinued. Her vision cyclophosphamide and total body irradiation. She received recovered completely after 48 h and the other symptoms cyclosporin A as prophylaxis for graft-versus-host disease.
    [Show full text]
  • Cortical Blindness: Etiology, Diagnosis, and Prognosis
    Cortical Blindness: Etiology, Diagnosis, and Prognosis Michael S. Aldrich, MD," Anthony G. Alessi, MD," Roy W. Beck, MD,$ and Sid Gilman, MDI We examined 15 patients with cortical blindness, reviewed the records of 10 others, and compared these 25 patients to those in previous studies of cortical blindness. Although cerebrovascular disease was the most common cause in ow series, surgery, particularly cardiac surgery, and cerebral angiography were also major causes. Only 3 patients denied their blindness, although 4 others were unaware of their visual loss. Electroencephalograms (EEGs) were performed during the period of blindness in 20 patients and all recordings were abnormal, with absent alpha rhythm. Visual evoked potentials recorded during blindness were abnormal in 15 of 19 patients, but did not correlate with the severity of visual loss or with outcome. Bioccipital lucencies were found in computed tomographic (CT) scans of 14 patients; none of the 14 regained good vision. Recovery of vision was poor in all 8 patients who had a spontaneous stroke, but fair or good in 11 of the other 17 patients. Prognosis was best in patients under the age of 40 years, in those without a history of hypertension or diabetes mellitus, and in those without associated cognitive, language, or memory impair- ments. We conclude that (1) the prognosis in cortical blindness is poor when caused by stroke; (2) EEGs are more useful than visual evoked potentials for diagnosis; and (3) bioccipital abnormalities shown on CT scan are associated with a poor prognosis. Aldrich MS, Alessi AG, Beck RW, Gilman S: Cortical blindness: etiology, diagnosis, and prognosis.
    [Show full text]
  • Bilateral Cortical Blindness Due to Bilateral Occipital Infarcts Without Anosognosia
    Journal of Neurology & Stroke Bilateral Cortical Blindness due to Bilateral Occipital Infarcts without Anosognosia Abstract Case Report Bilateral cortical blindness refers to the total loss of vision in the presence of Volume 4 Issue 1- 2016 normal pupillary reflexes and in the absence of Ophthalmological disease resulting from bilateral lesions of the striate cortex in the occipital lobes. In most cases, these patients deny their blindness and their behavior is as if they have an intact vision. We report the case of an 84-year-old man with bilateral cortical blindness resulting from bilateral occipital lobe infarcts. The patient presented this infrequent clinical condition after acute bilateral infarction of the occipital 1First Propedeutic Department of Internal Medicine, lobes possibly due to cardiac embolism resulting from atrial fibrillation of Aristotle University of Thessaloniki, Greece unknown duration. Subcutaneous administration of low molecular weight heparin 2First Department of Neurology, Aristotle University of in therapeutic doses resulted in neurological improvement in the first four days. Thessaloniki, Greece Interestingly, the visual symptoms were complicated neither by anosognosia 3First Department of Ophthalmology, Aristotle University of nor by memory impairment. Cortical blindness and Anton’s syndrome should Thessaloniki, Greece be considered in patients with atypical visual loss and evidence of occipital lobe 4Department of Radiology, Aristotle University of injury. Cerebrovascular disease could be the background
    [Show full text]
  • THE CLINICAL ASSESSMENT of the PATIENT with EARLY DEMENTIA S Cooper, J D W Greene V15
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2005.081133 on 16 November 2005. Downloaded from THE CLINICAL ASSESSMENT OF THE PATIENT WITH EARLY DEMENTIA S Cooper, J D W Greene v15 J Neurol Neurosurg Psychiatry 2005;76(Suppl V):v15–v24. doi: 10.1136/jnnp.2005.081133 ementia is a clinical state characterised by a loss of function in at least two cognitive domains. When making a diagnosis of dementia, features to look for include memory Dimpairment and at least one of the following: aphasia, apraxia, agnosia and/or disturbances in executive functioning. To be significant the impairments should be severe enough to cause problems with social and occupational functioning and the decline must have occurred from a previously higher level. It is important to exclude delirium when considering such a diagnosis. When approaching the patient with a possible dementia, taking a careful history is paramount. Clues to the nature and aetiology of the disorder are often found following careful consultation with the patient and carer. A focused cognitive and physical examination is useful and the presence of specific features may aid in diagnosis. Certain investigations are mandatory and additional tests are recommended if the history and examination indicate particular aetiologies. It is useful when assessing a patient with cognitive impairment in the clinic to consider the following straightforward questions: c Is the patient demented? c If so, does the loss of function conform to a characteristic pattern? c Does the pattern of dementia conform to a particular pattern? c What is the likely disease process responsible for the dementia? An understanding of cognitive function and its anatomical correlates is necessary in order to ascertain which brain areas are affected.
    [Show full text]
  • 1 Cerebrospinal Fluid Neurofilament Light Is Associated with Survival In
    1 Cerebrospinal fluid Neurofilament Light is associated with survival in mitochondrial disease patients Kalliopi Sofou†,a, Pashtun Shahim†, b,c, Már Tuliniusa, Kaj Blennowb,c, Henrik Zetterbergb,c,d,e, Niklas Mattssonf, Niklas Darina aDepartment of Pediatrics, University of Gothenburg, The Queen Silvia’s Children Hospital, Gothenburg, Sweden bInstitute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, the Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden. cClinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden dDepartment of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK eUK Dementia Research Institute at UCL, London, UK fClinical Memory Research Unit, Lund University, Malmö, Sweden, and Lund University, Skåne University Hospital, Department of Clinical Sciences, Neurology, Lund, Sweden †Equal contributors Correspondence to: Kalliopi Sofou, MD, PhD Department of Pediatrics University of Gothenburg, The Queen Silvia’s Children Hospital SE-416 85 Gothenburg, Sweden Tel: +46 (0) 31 3421000 E-mail: [email protected] Abbreviations Ab42 Amyloid-b42 AD Alzheimer’s disease AUROC Area under the receiver operating-characteristic curve CNS Central nervous system CSF Cerebrospinal fluid DWI Diffusion weighted imaging FLAIR Fluid attenuated inversion recovery GFAp Glial fibrillary acidic protein KSS Kearns-Sayre syndrome LP Lumbar puncture ME Mitochondrial encephalopathy Mitochondrial encephalomyopathy, lactic acidosis and MELAS stroke-like
    [Show full text]
  • Drugs for Orphan Mitochondrial Disease
    Drugs for Orphan Mitochondrial Disease Gino Cortopassi, CEO Ixchel:Mayan goddess of health www.ixchelpharma.com Davis, CA Executive Summary • Ixchel is a clinical stage company focused on developing IXC-109 as therapeutic for mitochondrial diseases: 109 increases mitochondrial activities in cells & mice. • XC-109 is an NCE prodrug of the active moiety Mono-methylfumarate (MMF) upon which a Composition-of-Matter patent has been applied for. • IP: rights to 5 patent families, including composition of matter, method of use, formulation and 2 granted orphan drug designations. • Efficacy: demonstrated efficacy in preclinical mouse models with IXC-109 in Leigh’s Syndrome, Friedreich’s ataxia cardiac defects. • Patient advocacy groups & KOLs: Ixchel developed a 10-year relationship with patient advocacy groups FARA, Ataxia UK, UMDF & MDA, and networks with 8 Key Opinion Leaders in Mitochondrial Research and Mitochondrial Disease clinical development • Proven path and comps – Valuation of other MMF prodrugs: Vumerity/Alkermes 8700, Xenoport/Dr. Reddy’s – Valuation of Reata FA – IXC-109 is pharmacokinetically superior to Biogen’s DMF and Vumerity 2 Ixchel’s pipeline in orphan mitochondrial disease Benefits in Benefits in Patient Cells Target Identified Orphan Mitochondrial: Mouse models POC clinical trial Friedreich’s Ataxia, IXC103 Leigh’s Syndrome, LHON Mitochondrial Myopathy, IXC109 Duchenne’s Muscular Dystrophy 3 Defects of mitochondria are inherited and cause disease Neurodegeneration Friedreich’s ataxia Mitochondrial defect Genetics Leber’s (LHON) Myopathy Leigh Syndrome Muscle Wasting MELAS 4 Friedreich’s Ataxia as mitochondrial disease target for therapy FA as an orphan therapeutic target: § FA is the most prevalent inherited ataxia: ~6000 in North America, 15,000 Europe.
    [Show full text]
  • Patients with Cortical Blindness Who Do Not Have Any Residual Functional Vision, Talking Devices Can Be Given, I.E
    Title: Reading Ability spared in a case of Acquired Cortical Blindness, Neuroplasticity or Left posterior occipitotemporal sulcus sparing? Authors: Kim Ly, OD, Andrea L. Murphy, OD, FAAO Dorothy L. Hitchmoth, OD, FAAO, ABO, ABCMO Abstract: A patient with complete cortical blindness, as a result of sequential, bilateral occipital strokes, is able to read with occasional accuracy despite no evidence of macular field sparing and no light perception bilaterally. Case History Patient Demographics and Social History: o 58 year-old white male presents to his visit: . Accompanied by his ex-wife . Using sighted guide and a rolling walker for ambulation . Reporting he is in the process of moving in with his son for full-time caregiver support, previously homeless Chief Complaint o Primary complaint of loss of vision: . Started about 1 year ago after a “stroke” . Patient reports loss of vision following: the left half of his visual field in his left eye and "less than one half" in his right eye . A second stroke two months ago caused “complete blindness” . Patient and ex-wife report that patient can still read on occasion, i.e. directions on their car's GPS system or brochures o Secondary Complaint: . Gritty eyes that burn throughout the day Ocular History o Blindness OU o Patient did not report any other ocular history Medical History o Cerebrovascular accident (CVA) of the right occipital lobe secondary to cardiac embolus formation as a result of atrial fibrillation 10/2015 o Cerebrovascular accident affecting the left occipital lobe 6/2016
    [Show full text]
  • Recurrent Posterior Reversible Encephalopathy Syndrome (PRES)
    Journal of Human Hypertension (2004) 18, 287–289 & 2004 Nature Publishing Group All rights reserved 0950-9240/04 $25.00 www.nature.com/jhh CASE REPORT Recurrent posterior reversible encephalopathy syndrome (PRES) G Hagemann1, T Ugur1, OW Witte1 and C Fitzek2 1Department of Neurology, Friedrich-Schiller-University, Jena, Germany; 2Institute of Diagnostic and Interventional Radiology, Friedrich-Schiller-University, Jena, Germany Posterior reversible encephalopathy syndrome is a drome is usually fully reversible. We report a case of proposed cliniconeuroradiological entity characterized recurrent PRES of unknown aetiology following inten- by headache, altered mental status, cortical blindness, sive care unit treatment and only moderately elevated seizures, and other focal neurological signs, and a blood pressure. Clinicians as well as radiologists must diagnostic magnetic resonance imaging picture. A be familiar with this clinically frightening, underdiag- variety of different etiologies have been reported like nosed condition to assure timely diagnosis and treat- hypertension, pre-eclampsia/eclampsia, cyclosporin A ment to prevent persistent deficits. or tacrolimus neurotoxicity, uraemia and porphyria. Journal of Human Hypertension (2004) 18, 287–289. With early diagnosis and prompt treatment, the syn- doi:10.1038/sj.jhh.1001664 Keywords: PRES; reversible encephalopathy; cortical blindness Introduction ferred to a normal ward, she showed a fluctuating agitated confusional state that was accounted for as Posterior reversible encephalopathy syndrome a prolonged alcohol withdrawal syndrome. She was (PRES) is a proposed cliniconeuroradiological entity 1,2 given vitamins, haloperidol and benzodiazepines with a vast spectrum of different aetiologies. The and gradually recovered. After 27 days, she was able clinical hallmark of this syndrome are headache, to walk a few steps without assistance, was fully confusion, seizures, cortical visual disturbances or orientated and did not show any focal neurological blindness and, less common, other focal neurologi- abnormality.
    [Show full text]
  • Mitochondrial Genome Changes and Neurodegenerative Diseases☆
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1842 (2014) 1198–1207 Contents lists available at ScienceDirect Biochimica et Biophysica Acta journal homepage: www.elsevier.com/locate/bbadis Review Mitochondrial genome changes and neurodegenerative diseases☆ Milena Pinto a,c,CarlosT.Moraesa,b,c,⁎ a Department of Neurology, University of Miami Miller School of Medicine, Miami, FL 33136, USA b Neuroscience Graduate Program, University of Miami Miller School of Medicine, Miami, FL 33136, USA c Department of Cell Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA article info abstract Article history: Mitochondria are essential organelles within the cell where most of the energy production occurs by the oxida- Received 31 July 2013 tive phosphorylation system (OXPHOS). Critical components of the OXPHOS are encoded by the mitochondrial Received in revised form 6 November 2013 DNA (mtDNA) and therefore, mutations involving this genome can be deleterious to the cell. Post-mitotic tissues, Accepted 8 November 2013 such as muscle and brain, are most sensitive to mtDNA changes, due to their high energy requirements and non- Available online 16 November 2013 proliferative status. It has been proposed that mtDNA biological features and location make it vulnerable to mu- tations, which accumulate over time. However, although the role of mtDNA damage has been conclusively con- Keywords: Mitochondrion nected to neuronal impairment in mitochondrial diseases, its role in age-related neurodegenerative diseases mtDNA remains speculative. Here we review the pathophysiology of mtDNA mutations leading to neurodegeneration Encephalopathy and discuss the insights obtained by studying mouse models of mtDNA dysfunction.
    [Show full text]
  • Defined Neuronal Populations Drive Fatal Phenotype in a Mouse Model
    RESEARCH ARTICLE Defined neuronal populations drive fatal phenotype in a mouse model of Leigh syndrome Irene Bolea1,2†*, Alejandro Gella2,3†, Elisenda Sanz2,4,5†, Patricia Prada-Dacasa2,5, Fabien Menardy2, Angela M Bard4, Pablo Machuca-Ma´ rquez2, Abel Eraso-Pichot2, Guillem Mo` dol-Caballero2,5,6, Xavier Navarro2,5,6, Franck Kalume4,7,8, Albert Quintana1,2,4,5,9‡* 1Center for Developmental Therapeutics, Seattle Children’s Research Institute, Seattle, United States; 2Institut de Neurocie`ncies, Universitat Auto`noma de Barcelona, Bellaterra, Spain; 3Department of Biochemistry and Molecular Biology, Universitat Auto`noma de Barcelona, Bellaterra, Spain; 4Center for Integrative Brain Research, Seattle Children’s Research Institute, Seattle, United States; 5Department of Cell Biology, Physiology and Immunology, Universitat Auto`noma de Barcelona, Bellaterra, Spain; 6Centro de Investigacio´n Biome´dica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Bellaterra, Spain; 7Department of Neurological Surgery, University of Washington, Seattle, United States; 8Department of Pharmacology, University of Washington, Seattle, United States; 9Department of Pediatrics, University of Washington, Seattle, United States *For correspondence: [email protected] (IB); [email protected] (AQ) Mitochondrial deficits in energy production cause untreatable and fatal pathologies † Abstract These authors contributed known as mitochondrial disease (MD). Central nervous system affectation is critical in Leigh equally to this work Syndrome (LS), a common MD presentation, leading to motor and respiratory deficits, seizures and Present address: ‡Institut de premature death. However, only specific neuronal populations are affected. Furthermore, their Neurocie`ncies, Universitat molecular identity and their contribution to the disease remains unknown. Here, using a mouse Auto`noma de Barcelona, model of LS lacking the mitochondrial complex I subunit Ndufs4, we dissect the critical role of Bellaterra (Barcelona), Spain genetically-defined neuronal populations in LS progression.
    [Show full text]